INVESCO LTD (IVZ)

BMG491BT1088 - Common Stock

15.62  +0.04 (+0.26%)

After market: 15.62 0 (0%)

Fundamental Rating

4

Overall IVZ gets a fundamental rating of 4 out of 10. We evaluated IVZ against 208 industry peers in the Capital Markets industry. IVZ may be in some trouble as it scores bad on both profitability and health. IVZ is valued quite cheap, while showing a decent growth score. This is a good combination!



3

1. Profitability

1.1 Basic Checks

In the past year IVZ was profitable.
IVZ had a positive operating cash flow in the past year.
Of the past 5 years IVZ 4 years were profitable.
IVZ had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 2.03%, IVZ is in line with its industry, outperforming 42.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of 3.91%, IVZ is doing worse than 69.95% of the companies in the same industry.
IVZ has a Return On Invested Capital of 2.51%. This is in the lower half of the industry: IVZ underperforms 72.91% of its industry peers.
IVZ had an Average Return On Invested Capital over the past 3 years of 3.42%. This is significantly below the industry average of 9.80%.
Industry RankSector Rank
ROA 2.03%
ROE 3.91%
ROIC 2.51%
ROA(3y)1.8%
ROA(5y)1.66%
ROE(3y)3.73%
ROE(5y)3.79%
ROIC(3y)3.42%
ROIC(5y)3.67%

1.3 Margins

With a Profit Margin value of 10.38%, IVZ is not doing good in the industry: 64.53% of the companies in the same industry are doing better.
The Operating Margin of IVZ (15.91%) is worse than 68.47% of its industry peers.
In the last couple of years the Operating Margin of IVZ has declined.
IVZ has a better Gross Margin (68.45%) than 71.43% of its industry peers.
IVZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 15.91%
PM (TTM) 10.38%
GM 68.45%
OM growth 3Y-12.92%
OM growth 5Y-10.98%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.48%

2

2. Health

2.1 Basic Checks

The number of shares outstanding for IVZ has been reduced compared to 1 year ago.
Compared to 5 years ago, IVZ has more shares outstanding
The debt/assets ratio for IVZ is higher compared to a year ago.

2.2 Solvency

IVZ has an Altman-Z score of 0.94. This is a bad value and indicates that IVZ is not financially healthy and even has some risk of bankruptcy.
IVZ has a Altman-Z score (0.94) which is comparable to the rest of the industry.
IVZ has a debt to FCF ratio of 9.93. This is a negative value and a sign of low solvency as IVZ would need 9.93 years to pay back of all of its debts.
IVZ's Debt to FCF ratio of 9.93 is in line compared to the rest of the industry. IVZ outperforms 54.19% of its industry peers.
A Debt/Equity ratio of 0.56 indicates that IVZ is somewhat dependend on debt financing.
With a decent Debt to Equity ratio value of 0.56, IVZ is doing good in the industry, outperforming 66.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 9.93
Altman-Z 0.94
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

IVZ has a Current Ratio of 0.78. This is a bad value and indicates that IVZ is not financially healthy enough and could expect problems in meeting its short term obligations.
IVZ has a worse Current ratio (0.78) than 67.98% of its industry peers.
IVZ has a Quick Ratio of 0.78. This is a bad value and indicates that IVZ is not financially healthy enough and could expect problems in meeting its short term obligations.
IVZ has a Quick ratio of 0.78. This is in the lower half of the industry: IVZ underperforms 67.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78

4

3. Growth

3.1 Past

The earnings per share for IVZ have decreased strongly by -33.49% in the last year.
The Earnings Per Share has been decreasing by -9.08% on average over the past years.
Looking at the last year, IVZ shows a decrease in Revenue. The Revenue has decreased by -9.77% in the last year.
Measured over the past years, IVZ shows a small growth in Revenue. The Revenue has been growing by 1.47% on average per year.
EPS 1Y (TTM)-33.49%
EPS 3Y-8.01%
EPS 5Y-9.08%
EPS growth Q2Q2.94%
Revenue 1Y (TTM)-9.77%
Revenue growth 3Y-2.38%
Revenue growth 5Y1.47%
Revenue growth Q2Q-0.26%

3.2 Future

IVZ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.53% yearly.
Based on estimates for the next years, IVZ will show a quite strong growth in Revenue. The Revenue will grow by 8.27% on average per year.
EPS Next Y16.46%
EPS Next 2Y14.53%
EPS Next 3Y2.33%
EPS Next 5Y4.53%
Revenue Next Year2.19%
Revenue Next 2Y3.36%
Revenue Next 3Y8.27%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

7

4. Valuation

4.1 Price/Earnings Ratio

IVZ is valuated reasonably with a Price/Earnings ratio of 10.92.
Based on the Price/Earnings ratio, IVZ is valued a bit cheaper than 63.05% of the companies in the same industry.
IVZ is valuated cheaply when we compare the Price/Earnings ratio to 26.00, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.88, the valuation of IVZ can be described as reasonable.
Based on the Price/Forward Earnings ratio, IVZ is valued a bit cheaper than 71.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IVZ to the average of the S&P500 Index (21.38), we can say IVZ is valued rather cheaply.
Industry RankSector Rank
PE 10.92
Fwd PE 8.88

4.2 Price Multiples

IVZ's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IVZ is cheaper than 72.41% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IVZ is valued cheaper than 80.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.23
EV/EBITDA 12.95

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.66
PEG (5Y)N/A
EPS Next 2Y14.53%
EPS Next 3Y2.33%

5

5. Dividend

5.1 Amount

IVZ has a Yearly Dividend Yield of 5.10%, which is a nice return.
Compared to an average industry Dividend Yield of 7.98, IVZ has a dividend in line with its industry peers.
IVZ's Dividend Yield is rather good when compared to the S&P500 average which is at 2.48.
Industry RankSector Rank
Dividend Yield 5.1%

5.2 History

The dividend of IVZ has a limited annual growth rate of 1.42%.
IVZ has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of IVZ decreased in the last 3 years.
Dividend Growth(5Y)1.42%
Div Incr Years2
Div Non Decr Years2

5.3 Sustainability

IVZ pays out 98.96% of its income as dividend. This is not a sustainable payout ratio.
The dividend of IVZ is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.96%
EPS Next 2Y14.53%
EPS Next 3Y2.33%

INVESCO LTD

NYSE:IVZ (2/22/2024, 3:20:02 PM)

After market: 15.62 0 (0%)

15.62

+0.04 (+0.26%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.02B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 5.1%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 10.92
Fwd PE 8.88
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.66
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.03%
ROE 3.91%
ROCE
ROIC
ROICexc
ROICexgc
OM 15.91%
PM (TTM) 10.38%
GM 68.45%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.49%
EPS 3Y-8.01%
EPS 5Y
EPS growth Q2Q
EPS Next Y16.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-9.77%
Revenue growth 3Y-2.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y